Creative Planning’s Royalty Pharma RPRX Stock Holding History

Creative Planning’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.08M	Buy	144,174 +38,728	+37%	+$2.02M	﹤0.01%	1038
2026 Q1	$5.06M	Buy	105,446 +40,921	+63%	+$1.79M	﹤0.01%	1190
2025 Q4	$2.49M	Buy	64,525 +4,654	+8%	+$177K	﹤0.01%	1542
2025 Q3	$2.11M	Buy	59,871 +7,318	+14%	+$265K	﹤0.01%	1500
2025 Q2	$1.89M	Buy	52,553 +9,718	+23%	+$322K	﹤0.01%	1364
2025 Q1	$1.33M	Buy	42,835 +9,521	+29%	+$302K	﹤0.01%	1492
2024 Q4	$850K	Buy	33,314 +13,403	+67%	+$355K	﹤0.01%	1769
2024 Q3	$563K	Sell	19,911 -79	-0.4%	-$2.19K	﹤0.01%	1992
2024 Q2	$527K	Sell	19,990 -17,131	-46%	-$475K	﹤0.01%	1903
2024 Q1	$1.13M	Buy	37,121 +1,372	+4%	+$40.4K	﹤0.01%	1261
2023 Q4	$1M	Buy	35,749 +12,683	+55%	+$349K	﹤0.01%	1228
2023 Q3	$626K	Buy	+23,066	New	+$685K	﹤0.01%	1417

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's RPRX Position: Q2 2026 in Review

Creative Planning increased its Royalty Pharma (RPRX) stake by 37% in Q2 2026, buying an estimated $2.02M and bringing the position to 144,174 shares worth $8.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1038.

Creative Planning first reported a position in RPRX in Q3 2023 and has held it in 12 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Creative Planning held 144,174 shares of Royalty Pharma worth $8.08M as of Q2 2026.
Creative Planning bought 38,728 Royalty Pharma shares in Q2 2026, an estimated $2.02M.
Royalty Pharma made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1038 holding.
Creative Planning first reported a position in Royalty Pharma in Q3 2023 and has held it in 12 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.